ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 101 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $467,000 | -49.0% | 77,958 | -37.1% | 0.00% | -100.0% |
| Q4 2018 | $916,000 | -82.7% | 123,941 | -66.0% | 0.00% | -50.0% |
| Q3 2018 | $5,300,000 | +29.5% | 365,038 | +78.0% | 0.00% | -33.3% |
| Q2 2018 | $4,094,000 | +15.2% | 205,031 | +1.1% | 0.00% | +50.0% |
| Q1 2018 | $3,553,000 | -29.0% | 202,818 | 0.0% | 0.00% | -33.3% |
| Q4 2017 | $5,001,000 | -15.8% | 202,818 | -11.9% | 0.00% | -25.0% |
| Q3 2017 | $5,940,000 | +1.9% | 230,148 | +7.1% | 0.00% | 0.0% |
| Q2 2017 | $5,829,000 | +9.7% | 214,941 | +20.6% | 0.00% | 0.0% |
| Q1 2017 | $5,316,000 | +9.2% | 178,274 | -0.6% | 0.00% | 0.0% |
| Q4 2016 | $4,868,000 | +568.7% | 179,382 | +530.7% | 0.00% | – |
| Q3 2016 | $728,000 | +38.7% | 28,440 | 0.0% | 0.00% | – |
| Q2 2016 | $525,000 | +114.3% | 28,440 | +119.6% | 0.00% | – |
| Q1 2016 | $245,000 | -29.8% | 12,953 | 0.0% | 0.00% | – |
| Q4 2015 | $349,000 | – | 12,953 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Endurant Capital Management LP | 1,769,785 | $1,911,000 | 0.69% |
| Telemetry Investments, L.L.C. | 214,593 | $232,000 | 0.67% |
| Aisling Capital Management LP | 634,455 | $685,000 | 0.36% |
| Broadfin Capital, LLC | 1,620,000 | $1,750,000 | 0.32% |
| MFN Partners Management, LP | 1,500,000 | $1,620,000 | 0.24% |
| Sofinnova Investments, Inc. | 1,911,573 | $2,064,000 | 0.19% |
| Rock Springs Capital Management LP | 2,974,754 | $3,213,000 | 0.13% |
| Alambic Investment Management, L.P. | 150,636 | $163,000 | 0.12% |
| Cormorant Asset Management, LP | 250,000 | $270,000 | 0.02% |
| Man Group plc | 3,734,793 | $4,034,000 | 0.02% |